Medikal Fizik Çalışmaları

Size: px
Start display at page:

Download "Medikal Fizik Çalışmaları"

Transcription

1 Medikal Fizik Çalışmaları 9 Kasım Vildan ALPAN Amerikan Hastanesi MDACC Kanser Merkezi, İstanbul

2 Learning Objectives To get an overview of the main current research directions in radiation therapy physics Five abstracts selected based on (a) their high scores from reviewers (b) their relevance to this audience (c) variety in treatment sites To understand the clinical impact of physics research in radiation oncology

3 Major Themes Treatment Planning and Delivery (in SRS/SBRT) Incident Learning for Stereotactic Radiation Therapy from RO-ILS: Radiation Oncology Incident Learning System (liver SBRT) Imaging for Response Assessment / Outcome analysis and modeling Radiogenomic Analysis of a Peritumoral CT Image Feature and its Prognostic Value in Early Stage NSCLC Regional dose differences associated with radiation-induced acute severe dysphagia (for H&N tumors)

4 Incident Learning for Stereotactic Radiation Therapy from RO-ILS: Radiation Oncology Incident Learning System D. J. Hoopes 1, E. C. Ford 2, G. A. Ezzell 3, A. P. Dicker 4, B. S. Chera 5, and L. Potters 6 1 University of California, San Diego, La Jolla, CA, 2 University of Washington Medical Center, Seattle, WA, 3 Mayo Clinic Arizona, Phoenix, AZ, 4 Sidney Kimmel Medical College at Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, PA, 5 Department of Radiation Oncology, University of North Carolina School of Medicine, Chapel Hill, NC, 6 Department of Radiation Medicine, Northwell Health, Lake Success, NY

5 Study Design / Purpose/Objective(s) The mission of RO-ILS is to facilitate safer and higher quality care in radiation oncology by providing a mechanism for shared learning. It is a voluntary incident learning system sponsored by ASTRO and AAPM. More than 300 facilities participate and more than 3000 cases have been submitted. Incident Learning REPORT ANALYZE MAKE IMPROVMENTS This study: Examine the patterns of errors reported for Stereotactic Radiosurgery (SRS) and Stereotactic Body Radiation Therapy (SBRT) using RO-ILS Lung Example: Conventional (2Gy x 30) vs SBRT (18Gy x 3), i.e. potentially half the targeting margin for error in a tenth of the total delivery sessions SRS/SBRT incidents were compared to non-stereotactic incidents.

6 Results Feb 2014 to Dec 2016: 2681 total incidents submitted 217 (8%) incidents were SRS/SBRT (no distinction) 40% SRS/SBRT RO-ILS Incidents Severity Scores, n=217 38% 35% 30% 25% 20% 15% 10% 5% 18% 24% 16% 4% Common event types: incorrect shift/alignment collisions/clearance incorrect site incorrect contours 0% Severity Scores 1 (Low) (High)

7 Results Near-miss Therapeutic Radiation Incident Unsafe Condition Other Process Operational Improvement SRS/SBRT, n=217 40% 25% 24% 7% 4% Non-SRS/SRT, n= % 34% 28% P-value Radiation incident: Error that reached the patient, and may or may not have caused harm. Differences between stereotactic and non-stereotactic events were statistically significant. Not shown: One third of the stereotactic events involved multiple patients (potential systematic errors). Stereotactic incidents are more likely to be near misses and less likely to reach the patient than conventional incidents

8 Results Dose Deviation (n=217) No deviation 92% Organ at Risk (OAR) 1% <5% of target dose 6% 5-25% of target dose 1% % target dose None >100% of target dose <1% In 92% of reported incidents, the error cause no dose deviation!

9 Authors Conclusions Significant dose deviations are uncommon in RO-ILS despite the complexity and risk of SRS/SBRT SRS/SBRT incidents are less likely to reach the patient than conventional incidents (heightened quality assurance requirements?)

10 Comments PRO: Illustrates the value of the RO-ILS system (Manuscript Common error pathways seen in the RO- ILS data that demonstrate opportunities for improving treatment safety in press in PRO; Demonstrates common error pathways in radiation oncology (most importantly errors defining targets, errors in manual processes, error in chart checks): This analysis of RO-ILS event data underscores the truism that verifying inputs to a process is more effective than testing outputs, especially when the output testing (e.g. plan checking by physics) is unlikely to discover the faulty input (e.g. target definition). CON: Voluntary reporting may cause bias Unclear how this knowledge can be used to improve treatments other than increase awareness

11 Radiogenomic Analysis of a Peritumoral CT Image Feature and Its Prognostic Value in Early Stage NSCLC J. Lee 1, Y. Cui 2, M. F. Gensheimer 3, B. W. Loo Jr 3, M. Diehn 3, and R. Li 4 1 Stanford University, Palo Alto, CA, 2 Global Station for Quantum Medical Science and Engineering, Global Institution for Collaborative Research and Education (GI-CoRE), Hokkaido University, Sapporo, Japan, 3 Stanford Cancer Institute, Stanford, CA, 4 Stanford University, Stanford, CA

12 Study Design / Purpose/Objective(s) Early-Stage NSCLC Increased prevalence with screening. Excellent local control after surgery or SABR. Distant metastasis remains a major problem (20-30%). Biomarkers are need to inform adjuvant therapy. Typical Prognostic Imaging Biomarkers Tumor size: TNM staging Most radiomic studies focus on gross tumor only Tumor texture and morphology: less established Few look beyond the tumor and invaded surrounding tissue Study aims: Identify patients with high risk of relapse. Determine the prognostic value of pleural contact. Identify the molecular basis of pleural contact.

13 Study Design / Methods Pleural invasion has been shown to correlate with poor prognosis in resected NSCLC Simple attachment to pleura does not necessarily imply invasion. Quantitative PCI: quantify relation of tumor and surrounding pleura based on CT Retrospectively analyzed 7 NSCLC cohorts (n=1069). PCI = pleural contact length Dmax PCI: 0.5 2cm PCI: 1 Stage I only.

14 Study Design / Methods Cohorts 1-2: Discovery cohort (n=117; pre-treatment CT and outcomes available) and external validation cohort (n=88). Cohort 3: Publicly available (n=89) patients with both imaging and gene expression data to identify the molecular basis of PCI and build a gene expression-based surrogate (radiogenomic classifier). Cohorts 4-7: Further tested prognostic relevance using four datasets (n=775) with publically available gene expression data and linked survival information.

15 Overall survival Overall survival Results Cohorts 1-2: PCI was prognostic, while pleural attachment was not. A cutoff of 0.8, PCI stratified patients (when using both internal and external cohorts) PCI was associated with survival beyond age, gender, tumor size, histology. Correlation did hold for small and large tumor volumes Stanford cohort European cohort

16 Results Cohort 3: 89 patients with gene expression (1919 genes correlated with PCI) and CT image data Extracellular matrix (ECM) remodeling was enriched among genes correlated with PCI (false discovery rate (FDR)=0.005) Remodeling of the ECM plays an important role in cancer invasion/metastasis. Cohorts 4-7: 775 patients with gene expression and survival in GEO (gene expression omnibus). The genomic surrogate of PCI: stratified patients for overall survival in all 4 cohorts remained a strong, independent prognostic factor GSE30219

17 Results PCI significantly stratified patients for overall survival in both discovery (log-rank test P = ) and validation (log-rank test P = ) imaging cohorts. PCI stratified patients for distant metastasis in the discovery cohort (log-rank test P = ). PCI was significantly associated with genes related to extracellular matrix organization/disassembly and collagen catabolic process (Spearmen test P < 0.05). This suggests association between PCI and metastasis-prone tumor microenvironment. The radiogenomic classifier stratified patients for overall survival in each of four gene expression cohorts (log-rank test P range: < to 0.019) and remained an independent predictor when adjusting for age, gender, and tumor stage (Wald test P = ).

18 Authors Conclusions Pleural contact index (PCI) can serve as a noninvasive prognostic marker and might be used to guide risk-adapted therapy in early stage NSCLC. Tumors with higher PCI may be driven by ECM remodeling. Prospective studies are needed to confirm these findings. Radiogenomic strategy can be used to identify biological meaningful and clinical relevant imaging biomarkers in other cancer types.

19 Comments PRO: Biomarkers are needed that can reliably predict disease recurrence and more aggressive disease to guide the management of lung cancer considering the toxicities associated with chemotherapy. Association between imaging (PCI) and molecular (ECM) phenotypes. CON: Study shows correlative relations but not causative relations Retrospective study Many published prognostic markers simply correlate with tumor volume (study found moderate correlation between PCI and tumor volume in one cohort) Study has recently been published: Eur Radiol Aug 7

20 Regional dose differences associated with radiation-induced acute severe dysphagia S. Monti 1, G. Palma 2, V. D'Avino 2, M. Gerardi 3, D. Ciardo 3, D. Alterio 3, B. A. Jereczek-Fossa 3,4, M. Quarantelli 2, R. Pacelli 5, and L. Cella 2 1 IRCCS SDN, Napoli, Italy, 2 National Research Council, Institute of Biostructures and Bioimaging, Napoli, Italy, 3 Istituto Europeo di Oncologia, Milano, Italy, 4 Department of Oncology and Hematooncology, University of Milan, Milano, Italy, 5 Federico II University School of Medicine, Department of Advanced Biomedical Sciences, Napoli, Italy

21 Study Design / Purpose/Objective(s) To apply a voxel-based analysis (VBA) to explore correlation between radiation induced acute dysphagia (RIAD) and local dose release in patients treated for head and neck (H&N) tumors. Different dose distributions can have the same DVH! Alpha Bravo VBA permits to overcome the limitations of DVH-based or single organ analysis Definition and contouring of swallowing-related normal tissues can be time consuming and prone to operator variations

22 Study Design / Methods 42 Head & Neck (H&N) patients treated with definitive RT and no previous surgery: 23 3D CRT 19 IMRT Median total prescribed dose of 70 Gy (35 fractions of 2 Gy) 41 patients received concurrent (35/42) or induction (6/42) chemotherapy 9 patients developed a severe (CTCAE v4.0 grade 3) RIAD. None of the clinical variables showed a significant correlation with RIAD.

23 Study Design / Methods Planning CTs are registered to the common coordinate system (CCS) by an elastic image registration (EIR) tool. The obtained deformation fields are used to warp the dose maps into the CCS. A statistical mapping scheme (TFCE) is applied to extract the clusters of voxels (S 0.05 ) significantly associated with higher doses released in patients developing the radiation induced toxicity.

24 Results Dose distributions given to patients who (a) developed RIAD (b) did not developed RIAD The TFCE analysis showed that a significantly higher dose was delivered to RIAD patients in two voxel clusters (c) dose difference map (d) statistical significant dose difference located in the cricopharyngeus muscle and the cervical esophagus. (a) (c) (b) (d)

25 Results Dose differences between groups Overall S 0.05 volume = 5.1 cm 3 ; Mean dose in S 0.05 separates RIAD (median = 48 Gy) non-riad (median = 33 Gy) ROC-AUC = S 0.05

26 Authors Conclusions The work goes beyond the organ-based philosophy in the analysis of radiation induced toxicity in H&N H&N sites are challenging for registration process due to: High mobility of the structures Considerable inter-patient anatomical variability A correlation was found between RIAD and local dose differences in regions that are likely associated with the swallowing function

27 Comments PRO: Voxel based analysis does not require prior knowledge of anatomical regions Correlation between the dose delivered in a specific region of the swallowinginvolved organs and the RIAD onset can be exploited to construct an avoidance criterion in the planning optimization strategy. Data may allow further insight into spatial distribution of radiation sensitivity. CON: Patient variability (results apply to average patient) Small cohort Study has been published: Scientific Reports 7: 7220 (2017)

28 TEŞEKKÜRLER La Jolla/ San Diego

Novel techniques for normal tissue toxicity modelling. Laura Cella Institute of Biostructures and Bioimaging National Research Council of Italy

Novel techniques for normal tissue toxicity modelling. Laura Cella Institute of Biostructures and Bioimaging National Research Council of Italy Novel techniques for normal tissue toxicity modelling Laura Cella Institute of Biostructures and Bioimaging National Research Council of Italy Disclosure: I have no conflict of interest An honorarium is

More information

8/1/2017. Imaging and Molecular Biomarkers of Lung Cancer Prognosis. Disclosures. The Era of Precision Oncology

8/1/2017. Imaging and Molecular Biomarkers of Lung Cancer Prognosis. Disclosures. The Era of Precision Oncology Imaging and Molecular Biomarkers of Lung Cancer Prognosis Ruijiang Li, PhD Assistant Professor of Radiation Oncology 08/01/2017 Stanford University Department of Radiation Oncology School of Medicine Disclosures

More information

Medikal Fizik Çalışmaları

Medikal Fizik Çalışmaları Medikal Fizik Çalışmaları Zeynep Özen Acıbadem Altunizade Hastanesi Major Themes Treatment Planning and Delivery (in SRS/SBRT) Improving Quality and Consistency in Clinical Trials via Knowledge- Based

More information

Patient Safety in the Age of Big Data

Patient Safety in the Age of Big Data CIRMS 2018 Patient Safety in the Age of Big Data Machine Learning, Measurements, and Standards for Making Radiation Treatments Safer Christopher Berlind, PhD Co-founder and Chief Technology Officer, Oncora

More information

Stereotactic ablative radiotherapy in early NSCLC and metastases

Stereotactic ablative radiotherapy in early NSCLC and metastases Stereotactic ablative radiotherapy in early NSCLC and metastases Scheduled: 0810-0830 hrs, 10 March 2012 Professor Suresh Senan Department of Radiation Oncology SABR in stage I NSCLC A major treatment

More information

LONG-TERM SURGICAL OUTCOMES OF 1018 PATIENTS WITH EARLY STAGE NSCLC IN ACOSOG Z0030 (ALLIANCE) TRIAL

LONG-TERM SURGICAL OUTCOMES OF 1018 PATIENTS WITH EARLY STAGE NSCLC IN ACOSOG Z0030 (ALLIANCE) TRIAL LONG-TERM SURGICAL OUTCOMES OF 1018 PATIENTS WITH EARLY STAGE NSCLC IN ACOSOG Z0030 (ALLIANCE) TRIAL Stacey Su, MD; Walter J. Scott, MD; Mark S. Allen, MD; Gail E. Darling, MD; Paul A. Decker, MS; Robert

More information

Might Adaptive Radiotherapy in NSCLC be feasible in clinical practice?

Might Adaptive Radiotherapy in NSCLC be feasible in clinical practice? Might Adaptive Radiotherapy in NSCLC be feasible in clinical practice? E.Molfese, P.Matteucci, A.Iurato, L.E.Trodella, A.Sicilia, B.Floreno, S.Ramella, L.Trodella Radioterapia Oncologica, Università Campus

More information

SBRT in Pancreas Cancer Role of The Radiosurgery Society

SBRT in Pancreas Cancer Role of The Radiosurgery Society SBRT in Pancreas Cancer Role of The Radiosurgery Society Anand Mahadevan MD FRCS FRCR Chairman Division of Radiation Oncology Geisinger Health System, Danville, PA, USA. Past President and Chairman: The

More information

The Role of Radiation Therapy in the Treatment of Brain Metastases. Matthew Cavey, M.D.

The Role of Radiation Therapy in the Treatment of Brain Metastases. Matthew Cavey, M.D. The Role of Radiation Therapy in the Treatment of Brain Metastases Matthew Cavey, M.D. Objectives Provide information about the prospective trials that are driving the treatment of patients with brain

More information

Reirradiazione. La radioterapia stereotassica ablativa: torace. Pierluigi Bonomo Firenze

Reirradiazione. La radioterapia stereotassica ablativa: torace. Pierluigi Bonomo Firenze Reirradiazione La radioterapia stereotassica ablativa: torace Pierluigi Bonomo Firenze Background Stage III NSCLC isolated locoregional recurrence in 25% of pts mostly unresectable; low RR with 2 nd line

More information

Insights into Thymic Epithelial Tumors: Radiation Therapy

Insights into Thymic Epithelial Tumors: Radiation Therapy Insights into Thymic Epithelial Tumors: Radiation Therapy Charles R. Thomas, MD Professor and Chairman, Department of Radiation Medicine Professor, Department of Medicine, Division of Hematology/Medical

More information

Flattening Filter Free beam

Flattening Filter Free beam Dose rate effect in external radiotherapy: biology and clinic Marta Scorsetti, M.D. Radiotherapy and Radiosurgery Dep., Istituto Clinico Humanitas, Milan, Italy Brescia October 8th/9th, 2015 Flattening

More information

Beyond the DVH: Voxelbased Automated Planning and Quality Assurance

Beyond the DVH: Voxelbased Automated Planning and Quality Assurance 1 Beyond the DVH: Voxelbased Automated Planning and Quality Assurance Presented by Chris McIntosh Research Associate Department of Medical Imaging & Physics Princess Margaret Cancer Centre C. McIntosh

More information

8/10/2016. PET/CT Radiomics for Tumor. Anatomic Tumor Response Assessment in CT or MRI. Metabolic Tumor Response Assessment in FDG-PET

8/10/2016. PET/CT Radiomics for Tumor. Anatomic Tumor Response Assessment in CT or MRI. Metabolic Tumor Response Assessment in FDG-PET PET/CT Radiomics for Tumor Response Evaluation August 1, 2016 Wei Lu, PhD Department of Medical Physics www.mskcc.org Department of Radiation Oncology www.umaryland.edu Anatomic Tumor Response Assessment

More information

Disclosures. Overview 8/3/2016. SRS: Cranial and Spine

Disclosures. Overview 8/3/2016. SRS: Cranial and Spine SRS: Cranial and Spine Brian Winey, Ph.D. Department of Radiation Oncology Massachusetts General Hospital Harvard Medical School Disclosures Travel and research funds from Elekta Travel funds from IBA

More information

NCCN GUIDELINES ON PROTON THERAPY (AS OF 4/23/18) BONE (Version , 03/28/18)

NCCN GUIDELINES ON PROTON THERAPY (AS OF 4/23/18) BONE (Version , 03/28/18) BONE (Version 2.2018, 03/28/18) NCCN GUIDELINES ON PROTON THERAPY (AS OF 4/23/18) Radiation Therapy Specialized techniques such as intensity-modulated RT (IMRT); particle beam RT with protons, carbon ions,

More information

The Smart Way to Check Treatment Plans and Charts. Anne W. Greener, Ph.D., FACR American Association Of Medical Dosimetrists June 15, 2016

The Smart Way to Check Treatment Plans and Charts. Anne W. Greener, Ph.D., FACR American Association Of Medical Dosimetrists June 15, 2016 The Smart Way to Check Treatment Plans and Charts Anne W. Greener, Ph.D., FACR American Association Of Medical Dosimetrists June 15, 2016 Conflicts NONE Professional Affiliations AAPM Liaison to the AAMD

More information

The TomoTherapy System as a Tool of Differentiation in Quality and Marketability

The TomoTherapy System as a Tool of Differentiation in Quality and Marketability The TomoTherapy System as a Tool of Differentiation in Quality and Marketability John J. Kresl, MD, PhD, FACRO, FACR Medical Director Phoenix CyberKnife & Radiation Oncology Center Managing Partner Phoenix,

More information

A Population-Based Study on the Uptake and Utilization of Stereotactic Radiosurgery (SRS) for Brain Metastasis in Nova Scotia

A Population-Based Study on the Uptake and Utilization of Stereotactic Radiosurgery (SRS) for Brain Metastasis in Nova Scotia A Population-Based Study on the Uptake and Utilization of Stereotactic Radiosurgery (SRS) for Brain Metastasis in Nova Scotia Gaurav Bahl, Karl Tennessen, Ashraf Mahmoud-Ahmed, Dorianne Rheaume, Ian Fleetwood,

More information

U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland Distribution Unlimited

U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland Distribution Unlimited AWARD NUMBER: W81XWH-12-1-0236 TITLE: PRINCIPAL INVESTIGATOR: EF5 PET of Tumor Hypoxia: A Predictive Imaging Biomarker of Response to Stereotactic Ablative Radiotherapy (SABR) for Early Lung Cancer Billy

More information

Defining Target Volumes and Organs at Risk: a common language

Defining Target Volumes and Organs at Risk: a common language Defining Target Volumes and Organs at Risk: a common language Eduardo Rosenblatt Section Head Applied Radiation Biology and Radiotherapy (ARBR) Section Division of Human Health IAEA Objective: To introduce

More information

AdvaMed Medtech Value Assessment Framework in Practice

AdvaMed Medtech Value Assessment Framework in Practice AdvaMed Medtech Value Assessment Framework in Practice Application of the Medtech Value Assessment Framework to Stereotactic Body Radiation Therapy for Non-Small Cell Lung Cancer Value Framework Overview

More information

QUARTERLY REPORT PATIENT SAFETY WORK PRODUCT Q J A N UA RY 1, 2016 MA R C H 31, 2016

QUARTERLY REPORT PATIENT SAFETY WORK PRODUCT Q J A N UA RY 1, 2016 MA R C H 31, 2016 QUARTERLY REPORT PATIENT SAFETY WORK PRODUCT Q1 2016 J A N UA RY 1, 2016 MA R C H 31, 2016 CLARITY PSO, a Division of Clarity Group, Inc. 8725 West Higgins Road Suite 810 Chicago, IL 60631 T: 773.864.8280

More information

De-Escalate Trial for the Head and neck NSSG. Dr Eleanor Aynsley Consultant Clinical Oncologist

De-Escalate Trial for the Head and neck NSSG. Dr Eleanor Aynsley Consultant Clinical Oncologist De-Escalate Trial for the Head and neck NSSG Dr Eleanor Aynsley Consultant Clinical Oncologist 3 HPV+ H&N A distinct disease entity Leemans et al., Nature Reviews, 2011 4 Good news Improved response to

More information

Clinical Protontherapy Head and Neck cancer

Clinical Protontherapy Head and Neck cancer Clinical Protontherapy Head and Neck cancer Coen Rasch Department of Radiation Oncology Academic Medical Center Amsterdam No disclosures 1 Introduction Proton vsphotonin the literature Model basedindicationprotocol

More information

Marco Trovò CRO-Aviano

Marco Trovò CRO-Aviano From pre-clinical research to clinical practice in radiation therapy: new predictive factors and biological markers to predict normal tissue toxicity after radiation therapy of the lung. Marco Trovò CRO-Aviano

More information

Linac Based SBRT for Low-intermediate Risk Prostate Cancer in 5 Fractions: Preliminary Report of a Phase II Study with FFF Delivery

Linac Based SBRT for Low-intermediate Risk Prostate Cancer in 5 Fractions: Preliminary Report of a Phase II Study with FFF Delivery Linac Based SBRT for Low-intermediate Risk Prostate Cancer in 5 Fractions: Preliminary Report of a Phase II Study with FFF Delivery FILIPPO ALONGI MD Radiation Oncology & Radiosurgery Istituto Clinico

More information

Improving the Diagnostic Specificity of CT for Early Detection of Lung Cancer: 4D CT-Based Pulmonary Nodule Elastometry. Menlo Park, CA

Improving the Diagnostic Specificity of CT for Early Detection of Lung Cancer: 4D CT-Based Pulmonary Nodule Elastometry. Menlo Park, CA AWARD NUMBER: W81XWH-12-1-0287 TITLE: Improving the Diagnostic Specificity of CT for Early Detection of Lung Cancer: 4D CT-Based Pulmonary Nodule Elastometry PRINCIPAL INVESTIGATOR: Billy Loo Jr., MD PhD

More information

TIP SHEET: TARGETED RADIATION FOR CHILDHOOD CANCER AND PROGRESS IN LOWERING TREATMENT COSTS AMONG RESEARCH PRESENTATIONS BY JOHNS HOPKINS SCIENTISTS

TIP SHEET: TARGETED RADIATION FOR CHILDHOOD CANCER AND PROGRESS IN LOWERING TREATMENT COSTS AMONG RESEARCH PRESENTATIONS BY JOHNS HOPKINS SCIENTISTS Johns Hopkins Kimmel Cancer Center Office of Public Affairs Media Contacts: Vanessa Wasta, 410-614-2916, wasta@jhmi.edu Amy Mone, 410-614-2915, amone@jhmi.edu TIP SHEET: TARGETED RADIATION FOR CHILDHOOD

More information

REVISITING ICRU VOLUME DEFINITIONS. Eduardo Rosenblatt Vienna, Austria

REVISITING ICRU VOLUME DEFINITIONS. Eduardo Rosenblatt Vienna, Austria REVISITING ICRU VOLUME DEFINITIONS Eduardo Rosenblatt Vienna, Austria Objective: To introduce target volumes and organ at risk concepts as defined by ICRU. 3D-CRT is the standard There was a need for a

More information

and Strength of Recommendations

and Strength of Recommendations ASTRO with ASCO Qualifying Statements in Bold Italics s patients with T1-2, N0 non-small cell lung cancer who are medically operable? 1A: Patients with stage I NSCLC should be evaluated by a thoracic surgeon,

More information

Pancreatic Cancer and Radiation Therapy

Pancreatic Cancer and Radiation Therapy Pancreatic Cancer and Radiation Therapy Why? Is there a role for local therapy with radiation in a disease with such a high rate of distant metastases? When? Resectable Disease Is there a role for post-op

More information

Stereotactic MR-guided adaptive radiation therapy (SMART) for locally advanced pancreatic tumors

Stereotactic MR-guided adaptive radiation therapy (SMART) for locally advanced pancreatic tumors Stereotactic MR-guided adaptive radiation therapy (SMART) for locally advanced pancreatic tumors Anna Bruynzeel, Radiation Oncologist VU University Medical Center, Amsterdam, The Netherlands Current standard

More information

Outline. WBRT field. Brain Metastases. Whole Brain RT Prophylactic WBRT Stereotactic radiosurgery (SRS) 1 fraction Stereotactic frame

Outline. WBRT field. Brain Metastases. Whole Brain RT Prophylactic WBRT Stereotactic radiosurgery (SRS) 1 fraction Stereotactic frame Radiation Therapy for Advanced NSC Lung Ca Alexander Gottschalk, M.D., Ph.D. Associate Professor Director of CyberKnife Radiosurgery Department of Radiation Oncology University of California San Francisco

More information

CALGB Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer

CALGB Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer CALGB 30610 Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer Jeffrey A. Bogart Department of Radiation Oncology Upstate Medical University Syracuse, NY Small Cell Lung Cancer Estimated 33,000

More information

Automated Plan Quality Check with Scripting. Rajesh Gutti, Ph.D. Clinical Medical Physicist

Automated Plan Quality Check with Scripting. Rajesh Gutti, Ph.D. Clinical Medical Physicist Automated Plan Quality Check with Scripting Rajesh Gutti, Ph.D. Clinical Medical Physicist Veera.Gutti@BSWHealth.org Outline Introduction - BSW Automation in Treatment planning Eclipse Scripting API Script

More information

Pre- Versus Post-operative Radiotherapy

Pre- Versus Post-operative Radiotherapy Postoperative Radiation and Chemoradiation: Indications and Optimization of Practice Dislosures Clinical trial support from Genentech Inc. Sue S. Yom, MD, PhD Associate Professor UCSF Radiation Oncology

More information

Radiation Therapy for Liver Malignancies

Radiation Therapy for Liver Malignancies Outline Radiation Therapy for Liver Malignancies Albert J. Chang, M.D., Ph.D. Department of Radiation Oncology, UCSF March 23, 2014 Rationale for developing liver directed therapies Liver directed therapies

More information

8/2/2018. Disclosure. Online MR-IG-ART Dosimetry and Dose Accumulation

8/2/2018. Disclosure. Online MR-IG-ART Dosimetry and Dose Accumulation Online MR-IG-ART Dosimetry and Dose Accumulation Deshan Yang, PhD, Associate Professor Department of Radiation Oncology, School of Medicine Washington University in Saint Louis 1 Disclosure Received research

More information

CON: Removal of the Breast Primary in Patients with Metastatic Breast Cancer

CON: Removal of the Breast Primary in Patients with Metastatic Breast Cancer CON: Removal of the Breast Primary in Patients with Metastatic Breast Cancer Amelia B. Zelnak, M.D., M.Sc. Assistant Professor of Hematology and Medical Oncology Winship Cancer Institute Emory University

More information

San Antonio Breast Cancer Symposium 2010 Highlights Radiotherapy

San Antonio Breast Cancer Symposium 2010 Highlights Radiotherapy San Antonio Breast Cancer Symposium 2010 Highlights Radiotherapy Kathleen C. Horst, M.D. Assistant Professor Department of Radiation Oncology Stanford University The Optimal SEquencing of Adjuvant Chemotherapy

More information

Patient-Specific QA & QA Process. Sasa Mutic, Ph.D. Washington University School of Medicine

Patient-Specific QA & QA Process. Sasa Mutic, Ph.D. Washington University School of Medicine Patient-Specific QA & QA Process Sasa Mutic, Ph.D. Washington University School of Medicine Outline of Presentation QA and QC in RT Safety vs. quality Patient specific QM program Learning Objectives Describe

More information

An Update on Radiation Therapy for Prostate Cancer

An Update on Radiation Therapy for Prostate Cancer An Update on Radiation Therapy for Prostate Cancer David C. Beyer, MD, FACR, FACRO, FASTRO Arizona Oncology Services Phoenix, Arizona Objectives Review significant new data Identify leading trends in PCa

More information

A Prospective Phase II Trial of Deintensified Chemoradiation Therapy for Low Risk HPV Associated Oropharyngeal Squamous Cell Carcinoma

A Prospective Phase II Trial of Deintensified Chemoradiation Therapy for Low Risk HPV Associated Oropharyngeal Squamous Cell Carcinoma A Prospective Phase II Trial of Deintensified Chemoradiation Therapy for Low Risk HPV Associated Oropharyngeal Squamous Cell Carcinoma B. S. Chera 1, R. J. Amdur 2, J. E. Tepper 3, B. Qaqish 4, R. Green

More information

The 16th KJC Bioinformatics Symposium Integrative analysis identifies potential DNA methylation biomarkers for pan-cancer diagnosis and prognosis

The 16th KJC Bioinformatics Symposium Integrative analysis identifies potential DNA methylation biomarkers for pan-cancer diagnosis and prognosis The 16th KJC Bioinformatics Symposium Integrative analysis identifies potential DNA methylation biomarkers for pan-cancer diagnosis and prognosis Tieliu Shi tlshi@bio.ecnu.edu.cn The Center for bioinformatics

More information

MRI Applications in Radiation Oncology:

MRI Applications in Radiation Oncology: MRI Applications in Radiation Oncology: Physician s Perspective Jeff Olsen, MD Department of Radiation Oncology Washington University, St. Louis, MO Disclosures Washington University has research and service

More information

Clinical Study Clinical Outcomes of Stereotactic Body Radiotherapy for Patients with Lung Tumors in the State of Oligo-Recurrence

Clinical Study Clinical Outcomes of Stereotactic Body Radiotherapy for Patients with Lung Tumors in the State of Oligo-Recurrence Pulmonary Medicine Volume 2012, Article ID 369820, 5 pages doi:10.1155/2012/369820 Clinical Study Clinical Outcomes of Stereotactic Body Radiotherapy for Patients with Lung Tumors in the State of Oligo-Recurrence

More information

8/2/2017. Improving Dose Prescriptions for Safety, Reporting, and Clinical Guideline Consistency. Part III

8/2/2017. Improving Dose Prescriptions for Safety, Reporting, and Clinical Guideline Consistency. Part III Improving Dose Prescriptions for Safety, Reporting, and Clinical Guideline Consistency Part III I Das, J Moran, M Langer Keeping Guidelines On Track: The Effect On Clinical Practice of Neglecting Guidelines

More information

Where are we with radiotherapy for biliary tract cancers?

Where are we with radiotherapy for biliary tract cancers? Where are we with radiotherapy for biliary tract cancers? Professor Maria A. Hawkins Associate Professor in Clinical Oncology MRC Group Leader/Honorary Consultant Clinical Oncologist CRUK MRC Oxford Institute

More information

Stereotactic Body Radiotherapy (SBRT) For HCC T A R E K S H O U M A N P R O F. R A D I A T I O N O N C O L O G Y N C I, C A I R O U N I V.

Stereotactic Body Radiotherapy (SBRT) For HCC T A R E K S H O U M A N P R O F. R A D I A T I O N O N C O L O G Y N C I, C A I R O U N I V. Stereotactic Body Radiotherapy (SBRT) For HCC T A R E K S H O U M A N P R O F. R A D I A T I O N O N C O L O G Y N C I, C A I R O U N I V. Hepatocellular carcinoma (HCC), is a major health problem worldwide.

More information

Overview of Clinical and Research Activities at Georgetown University Hospital

Overview of Clinical and Research Activities at Georgetown University Hospital Overview of Clinical and Research Activities at Georgetown University Hospital Dalong Pang, Ph.D. Department of Radiation Medicine Georgetown University Hospital Clinical Operation Two Varian linear accelerators

More information

National System for Incident Reporting in Radiation Therapy (NSIR-RT) Taxonomy

National System for Incident Reporting in Radiation Therapy (NSIR-RT) Taxonomy Canadian Partnership for Quality Radiotherapy (CPQR) National System for Incident Reporting in Radiation Therapy (NSIR-RT) National System for Incident Reporting in Radiation Therapy (NSIR-RT) Taxonomy

More information

Top Studies in Cancer Imaging and Radiation Therapy

Top Studies in Cancer Imaging and Radiation Therapy Top Studies in Cancer Imaging and Radiation Therapy Moderated by Julia White, MD, Ohio State University Comprehensive Cancer Center, and Michael Cohen, MD, Emory University Hepatic Function Model Based

More information

Medical Events. Florida Department of Health Division of Emergency Preparedness and Community Support Bureau of Radiation Control

Medical Events. Florida Department of Health Division of Emergency Preparedness and Community Support Bureau of Radiation Control Medical Events Florida Department of Health Division of Emergency Preparedness and Community Support Bureau of Radiation Control April 6, 2018 Presented by: Clark Eldredge Authority for Regulation Each

More information

Dosimetric Analysis of 3DCRT or IMRT with Vaginal-cuff Brachytherapy (VCB) for Gynaecological Cancer

Dosimetric Analysis of 3DCRT or IMRT with Vaginal-cuff Brachytherapy (VCB) for Gynaecological Cancer Dosimetric Analysis of 3DCRT or IMRT with Vaginal-cuff Brachytherapy (VCB) for Gynaecological Cancer Tan Chek Wee 15 06 2016 National University Cancer Institute, Singapore Clinical Care Education Research

More information

The RSS and ACRO Program for Distinction in Stereotactic Radiation Therapy

The RSS and ACRO Program for Distinction in Stereotactic Radiation Therapy The RSS and ACRO Program for Distinction in Stereotactic Radiation Therapy Practical Medical Physics: Radiation Oncology Accreditation Programs AAPM Annual Meeting, Nashville, TN July 30, 7:30-9:30 Presented

More information

Imaging e tecnologia: cosa c è dietro l angolo?

Imaging e tecnologia: cosa c è dietro l angolo? Reggio Emilia, 17 Aprile 2010 Imaging e tecnologia: cosa c è dietro l angolo? Claudio Fiorino Fisica Sanitaria Istituto Scientifico San Raffaele, Milano Premessa Imaging e RT.una lunga storia.. La RT attuale

More information

Quantitative Radiomics System Decoding the Tumor Phenotype. John Quackenbush and Hugo Aerts

Quantitative Radiomics System Decoding the Tumor Phenotype. John Quackenbush and Hugo Aerts Quantitative Radiomics System Decoding the Tumor Phenotype John Quackenbush and Hugo Aerts The Radiomics Hypothesis The tumor s structural phenotype reflects its molecular and clinical properties. This

More information

Treatment of oligometastases: Lung

Treatment of oligometastases: Lung Treatment of oligometastases: Lung Themadag Catharina ZH 30 March 2017 Max Dahele Radiation Oncologist Vumc, Amsterdam m.dahele@vumc.nl Do you all treat lung oligometastases? What is your definition of

More information

Palliative radiotherapy near the end of life for brain metastases from lung cancer: a populationbased

Palliative radiotherapy near the end of life for brain metastases from lung cancer: a populationbased Palliative radiotherapy near the end of life for brain metastases from lung cancer: a populationbased analysis Roel Schlijper Fellow Radiation Oncology BC Cancer, Prince George Disclosures No conflicts

More information

University of California, Los Angeles, Los Angeles, CA, 2 FROS Radiation Oncology and CyberKnife Center, Flushing, NY, 3

University of California, Los Angeles, Los Angeles, CA, 2 FROS Radiation Oncology and CyberKnife Center, Flushing, NY, 3 Long-Term Outcomes of Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Adenocarcinoma: A Multi-Institutional Consortium Study A. U. Kishan 1, A. Katz 2, C. A. Mantz 3, F. I.

More information

Therapy of Non-Operable early stage NSCLC

Therapy of Non-Operable early stage NSCLC SBRT Stage I NSCLC Therapy of Non-Operable early stage NSCLC Dr. Adnan Al-Hebshi MD, FRCR(UK), FRCP(C), ABR King Faisal Specialist Hospital & Research Centre This is our territory Early Stages NSCLC Surgical

More information

RTOG Lung Cancer Committee 2012 Clinical Trial Update. Wally Curran RTOG Group Chairman

RTOG Lung Cancer Committee 2012 Clinical Trial Update. Wally Curran RTOG Group Chairman RTOG Lung Cancer Committee 2012 Clinical Trial Update Wally Curran RTOG Group Chairman 1 RTOG Lung Committee: Active Trials Small Cell Lung Cancer Limited Stage (Intergroup Trial) Extensive Stage (RTOG

More information

MRI-Based Biomarkers of Therapeutic Response in Triple-Negative Breast Cancer

MRI-Based Biomarkers of Therapeutic Response in Triple-Negative Breast Cancer MRI-Based Biomarkers of Therapeutic Response in Triple-Negative Breast Cancer Daniel Golden Postdoctoral Scholar (Radiology) Stanford University Daniel Rubin Laboratory NCI Cancer Imaging Fellowship Seminar

More information

On the use of 4DCT derived composite CT images in treatment planning of SBRT for lung tumors

On the use of 4DCT derived composite CT images in treatment planning of SBRT for lung tumors On the use of 4DCT derived composite CT images in treatment planning of SBRT for lung tumors Zhe (Jay) Chen, Ph.D. Department of Therapeutic Radiology Yale University School of Medicine and Yale-New Haven

More information

The Itracacies of Staging Patients with Suspected Lung Cancer

The Itracacies of Staging Patients with Suspected Lung Cancer The Itracacies of Staging Patients with Suspected Lung Cancer Gerard A. Silvestri, MD,MS, FCCP Professor of Medicine Medical University of South Carolina Charleston, SC silvestri@musc.edu Staging Lung

More information

Lung cancer pleural invasion was recognized as a poor prognostic

Lung cancer pleural invasion was recognized as a poor prognostic Visceral pleural invasion classification in non small cell lung cancer: A proposal on the basis of outcome assessment Kimihiro Shimizu, MD a Junji Yoshida, MD a Kanji Nagai, MD a Mitsuyo Nishimura, MD

More information

Tecniche Radioterapiche U. Ricardi

Tecniche Radioterapiche U. Ricardi Tecniche Radioterapiche U. Ricardi UNIVERSITA DEGLI STUDI DI TORINO Should we always rely on stage? T4N0M0 Stage IIIB T2N3M0 Early stage NSCLC The treatment of choice for early-stage NSCLC is anatomic

More information

The Evolution of SBRT and Hypofractionation in Thoracic Radiation Oncology

The Evolution of SBRT and Hypofractionation in Thoracic Radiation Oncology The Evolution of SBRT and Hypofractionation in Thoracic Radiation Oncology (specifically, lung cancer) 2/10/18 Jeffrey Kittel, MD Radiation Oncology, Aurora St. Luke s Medical Center Outline The history

More information

Hypofractionated radiation therapy for glioblastoma

Hypofractionated radiation therapy for glioblastoma Hypofractionated radiation therapy for glioblastoma Luis Souhami, MD, FASTRO Professor McGill University Department of Oncology, Division of Radiation Oncology Montreal Canada McGill University Health

More information

Paolo Tini 1,3 M.D. :

Paolo Tini 1,3 M.D. : Correlazione tra espressione di Epidermal Growth Factor Receptor (EGFR) e Patterns di recidiva/progressione di malattia dopo trattamento radio-chemioterapico in pazienti affetti da Glioblastoma (GB). Paolo

More information

Development of an Expert Consensus Target Delineation Atlas for Thymic Cancers: Initial Quantitative Analysis of an Expert Survey.

Development of an Expert Consensus Target Delineation Atlas for Thymic Cancers: Initial Quantitative Analysis of an Expert Survey. Development of an Expert Consensus Target Delineation Atlas for Thymic Cancers: Initial Quantitative Analysis of an Expert Survey. Charles R. Thomas, Jr., MD, Jayashree Kalpathy-Cramer, PhD, Jehee Choi,

More information

International RT Clinical Trial Group Membership & Quality Control BY DR YING XIAO

International RT Clinical Trial Group Membership & Quality Control BY DR YING XIAO International RT Clinical Trial Group Membership & Quality Control BY DR YING XIAO Disclosures The Department of Radiation Oncology at Hospital of University of Pennsylvania has a research agreement with

More information

Adjuvant Therapy in Locally Advanced Head and Neck Cancer. Ezra EW Cohen University of Chicago. Financial Support

Adjuvant Therapy in Locally Advanced Head and Neck Cancer. Ezra EW Cohen University of Chicago. Financial Support Adjuvant Therapy in Locally Advanced Head and Neck Cancer Ezra EW Cohen University of Chicago Financial Support This program is made possible by an educational grant from Eli Lilly Oncology, who had no

More information

Lung Cancer Radiotherapy

Lung Cancer Radiotherapy Lung Cancer Radiotherapy Indications, Outcomes, and Impact on Survivorship Care Malcolm Mattes, MD Assistant Professor WVU Department of Radiation Oncology When people think about radiation, they think

More information

The Clinical Research E-News

The Clinical Research E-News Volume 2: ISSUE 6: March 24, 2010 The Clinical Research E-News SPECIAL ALERT: The annual JOG investigator Meeting will be held at 5pm on May 10, 2010 at the Loews Hotel. Now Open: AZ1071, A Phase II Study

More information

SBRT fundamentals. Outline 8/2/2012. Stereotactic Body Radiation Therapy Quality Assurance Educational Session

SBRT fundamentals. Outline 8/2/2012. Stereotactic Body Radiation Therapy Quality Assurance Educational Session Stereotactic Body Radiation Therapy Quality Assurance Educational Session J Perks PhD, UC Davis Medical Center, Sacramento CA SBRT fundamentals Extra-cranial treatments Single or small number (2-5) of

More information

Clinical Implications Of Dose Summation And Adaptation

Clinical Implications Of Dose Summation And Adaptation Clinical Implications Of Dose Summation And Adaptation Patrick Kupelian, M.D. Professor and Vice Chair University of California Los Angeles Department of Radiation Oncology pkupelian@mednet.ucla.edu August

More information

WHAT SHOULD WE DO WITH TUMOUR BUDDING IN EARLY COLORECTAL CANCER?

WHAT SHOULD WE DO WITH TUMOUR BUDDING IN EARLY COLORECTAL CANCER? CANCER STAGING TNM and prognosis in CRC WHAT SHOULD WE DO WITH TUMOUR BUDDING IN EARLY COLORECTAL CANCER? Alessandro Lugli, MD Institute of Pathology University of Bern Switzerland Maastricht, June 19

More information

New Radiation Treatment Modalities in the Treatment of Lung Cancer

New Radiation Treatment Modalities in the Treatment of Lung Cancer New Radiation Treatment Modalities in the Treatment of Lung Cancer David Perry, M.D. Chief, Radiation Oncology Medical Director, CyberKnife Radiosurgery Center Medstar Franklin Square Medical Center Definitions

More information

Radiation Oncology MOC Study Guide

Radiation Oncology MOC Study Guide Radiation Oncology MOC Study Guide The following study guide is intended to give a general overview of the type of material that will be covered on the Radiation Oncology Maintenance of Certification (MOC)

More information

Applying Tissue Phenomics to Colorectal Clinical Questions

Applying Tissue Phenomics to Colorectal Clinical Questions Applying Tissue Phenomics to Colorectal Clinical Questions International Symposium for Tissue Phenomics San Francisco October 2014 Peter Caie Senior Research Fellow University of St Andrews Systems Pathology

More information

Prostate Cancer Appraisal Addendum: Stereotactic Body Radiation Therapy (SBRT)

Prostate Cancer Appraisal Addendum: Stereotactic Body Radiation Therapy (SBRT) Prostate Cancer Appraisal Addendum: Stereotactic Body Radiation Therapy (SBRT) The Institute for Clinical and Economic Review (ICER) has published appraisals on multiple management options for clinically-localized,

More information

Clinical Trial Credentialing:

Clinical Trial Credentialing: IROC Mission Clinical Trial Credentialing: Provide integrated radiation oncology and diagnostic Where imaging to Start quality and control programs in support of the NCI s NCTN Network thereby Resources

More information

ART for Cervical Cancer: Dosimetry and Technical Aspects

ART for Cervical Cancer: Dosimetry and Technical Aspects ART for Cervical Cancer: Dosimetry and Technical Aspects D.A. Jaffray, Ph.D. Radiation Therapy Physics Princess Margaret Cancer Centre/Techna/Ontario Cancer Institute Professor Departments of Radiation

More information

QA for Clinical Dosimetry with Emphasis on Clinical Trials

QA for Clinical Dosimetry with Emphasis on Clinical Trials QA for Clinical Dosimetry with Emphasis on Clinical Trials Geoffrey S. Ibbott, Ph.D. and RPC Staff G. Ibbott, AAPM Summer School, June 24, 2009 1 QA Infrastructure for Clinical Trials Participating Institutions

More information

Protocolos de consenso: MTS Cerebrales Resumen ASTRO. Javier Aristu y Germán Valtueña Servicio Oncología Rad. Depart.

Protocolos de consenso: MTS Cerebrales Resumen ASTRO. Javier Aristu y Germán Valtueña Servicio Oncología Rad. Depart. Protocolos de consenso: MTS Cerebrales Resumen ASTRO Javier Aristu y Germán Valtueña Servicio Oncología Rad. Depart. ASTRO 2013 Brain met SRS Abstracts 97. Comparative Effectiveness of SRS versus WBRT

More information

TITLE: A Phase II Trial of Androgen Suppression and Radiation Therapy with Samarium-1 53 in Localized, High-Risk, Prostate Cancer

TITLE: A Phase II Trial of Androgen Suppression and Radiation Therapy with Samarium-1 53 in Localized, High-Risk, Prostate Cancer AD Award Number: W81XWH-04-1-0769 TITLE: A Phase II Trial of Androgen Suppression and Radiation Therapy with Samarium-1 53 in Localized, High-Risk, Prostate Cancer PRINCIPAL INVESTIGATOR: Richard K. Valicenti,

More information

CPT code semantics 8/18/2011. SBRT Planning Case Studies. Spectrum of applications of SBRT. itreat

CPT code semantics 8/18/2011. SBRT Planning Case Studies. Spectrum of applications of SBRT. itreat Spectrum of applications of SBRT EDUCATIONAL COURSE Physics and Dosimetry of SBRT Part III: Planning Case Studies Brian D. Kavanagh, MD, MPH Department of Radiation Oncology University of Colorado School

More information

Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010

Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010 LSU HEALTH SCIENCES CENTER NSCLC Guidelines Feist-Weiller Cancer Center Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010 Initial Evaluation/Intervention: 1. Pathology Review 2. History and Physical

More information

THE ROLE OF RADIATION THERAPY IN MANAGEMENT OF PANCREATIC ADENOCARCINOMA. TIMUR MITIN, MD, PhD

THE ROLE OF RADIATION THERAPY IN MANAGEMENT OF PANCREATIC ADENOCARCINOMA. TIMUR MITIN, MD, PhD THE ROLE OF RADIATION THERAPY IN MANAGEMENT OF PANCREATIC ADENOCARCINOMA TIMUR MITIN, MD, PhD RESECTABLE DISEASE MANAGEMENT: RESECTABLE DISEASE Resection offers the only possibility of long term survival

More information

Research and Reviews Journal of Medical and Clinical Oncology

Research and Reviews Journal of Medical and Clinical Oncology Comparison and Prognostic Analysis of Elective Nodal Irradiation Using Definitive Radiotherapy versus Chemoradiotherapy for Treatment of Esophageal Cancer Keita M 1,2, Zhang Xueyuan 1, Deng Wenzhao 1,

More information

Does the lung nodule look aggressive enough to warrant a more extensive operation?

Does the lung nodule look aggressive enough to warrant a more extensive operation? Accepted Manuscript Does the lung nodule look aggressive enough to warrant a more extensive operation? Michael Kuan-Yew Hsin, MBChB, MA, FRCS(CTh), David Chi-Leung Lam, MD, PhD, FRCP (Edin, Glasg & Lond)

More information

Introduction. The HER2 Testing Expert Panel has identified five Clinical Questions that form the core of this Focused Update.

Introduction. The HER2 Testing Expert Panel has identified five Clinical Questions that form the core of this Focused Update. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/ College of American Pathologists Clinical Practice Guideline Focused Update Wolff, et al. Introduction

More information

SBRT IN THE MANAGEMENT OF PROSTATE CANCER SATELLITE SYMPOSIUM AT THE AMERICAN SOCIETY FOR RADIATION ONCOLOGY (ASTRO) 2018 ANNUAL MEETING ADVANCES IN

SBRT IN THE MANAGEMENT OF PROSTATE CANCER SATELLITE SYMPOSIUM AT THE AMERICAN SOCIETY FOR RADIATION ONCOLOGY (ASTRO) 2018 ANNUAL MEETING ADVANCES IN DEPARTMENT OF RADIATION ONCOLOGY ADVANCES IN SBRT IN THE MANAGEMENT OF PROSTATE CANCER SATELLITE SYMPOSIUM AT THE AMERICAN SOCIETY FOR RADIATION ONCOLOGY (ASTRO) 2018 ANNUAL MEETING OCTOBER 21, 2018 MARRIOTT

More information

Chapters from Clinical Oncology

Chapters from Clinical Oncology Chapters from Clinical Oncology Lecture notes University of Szeged Faculty of Medicine Department of Oncotherapy 2012. 1 RADIOTHERAPY Technical aspects Dr. Elemér Szil Introduction There are three possibilities

More information

Potential conflicts-of-interest. Respiratory Gated and Four-Dimensional Tumor Tracking Radiotherapy. Educational objectives. Overview.

Potential conflicts-of-interest. Respiratory Gated and Four-Dimensional Tumor Tracking Radiotherapy. Educational objectives. Overview. Respiratory Gated and Four-Dimensional Tumor Tracking Radiotherapy Potential conflicts-of-interest I am PI of a sponsored research agreement between Stanford University and Varian Medical Systems P Keall

More information

Mehmet Ufuk ABACIOĞLU Neolife Medical Center, İstanbul, Turkey

Mehmet Ufuk ABACIOĞLU Neolife Medical Center, İstanbul, Turkey Updated Oncology 2015: State of the Art News & Challenging Topics CURRENT STATUS OF STEREOTACTIC RADIOSURGERY IN BRAIN METASTASES Mehmet Ufuk ABACIOĞLU Neolife Medical Center, İstanbul, Turkey Bucharest,

More information

Surgery versus stereotactic body radiation therapy in medically operable NSCLC

Surgery versus stereotactic body radiation therapy in medically operable NSCLC Surgery versus stereotactic body radiation therapy in medically operable NSCLC David H Harpole Jr, MD Professor of Surgery Associate Professor in Pathology Vice Chief, Division of Surgical Services Duke

More information

SBRT in early stage NSCLC

SBRT in early stage NSCLC SBRT in early stage NSCLC Optimal technique and tumor dose Frank Zimmermann Clinic of Radiotherapy and Radiation Oncology University Hospital Basel Petersgraben 4 CH 4031 Basel radioonkologiebasel.ch Techniques

More information